Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKesson
Express Scripts
US Department of Justice
AstraZeneca
Harvard Business School
Argus Health
Chubb
Cantor Fitzgerald
US Army

Generated: April 22, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,026,284

« Back to Dashboard

Which drugs does patent 8,026,284 protect, and when does it expire?

Patent 8,026,284 protects PROCYSBI and is included in one NDA.

Protection for PROCYSBI has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has fifteen patent family members in fifteen countries.
Summary for Patent: 8,026,284
Title:Enterically coated cystamine, cysteamine and derivatives thereof
Abstract: The disclosure provides oral cysteamine and cystamine formulations useful for treating cystinosis and neurodegenerative diseases and disorders. The formulations provide controlled release compositions that improve quality of life and reduced side-effects.
Inventor(s): Dohil; Ranjan (San Diego, CA), Schneider; Jerry (La Jolla, CA)
Assignee: The Regents of the University of California (Oakland, CA)
Application Number:11/990,869
Patent Claim Types:
see list of patent claims
Use; Composition; Delivery;

Drugs Protected by US Patent 8,026,284

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Horizon Pharma Usa PROCYSBI cysteamine bitartrate CAPSULE, DELAYED RELEASE;ORAL 203389-001 Apr 30, 2013 RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Horizon Pharma Usa PROCYSBI cysteamine bitartrate CAPSULE, DELAYED RELEASE;ORAL 203389-002 Apr 30, 2013 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 8,026,284

PCT Information
PCT FiledJanuary 26, 2007PCT Application Number:PCT/US2007/002325
PCT Publication Date:August 09, 2007PCT Publication Number: WO2007/089670

Non-Orange Book US Patents Family Members for Patent 8,026,284

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,198,882 Enterically coated cysteamine, cystamine and derivatives thereof ➤ Sign Up
9,511,039 Enterically coated cysteamine, cystamine and derivatives thereof ➤ Sign Up
9,750,708 Enterically coated cysteamine, cystamine and derivatives thereof ➤ Sign Up
8,129,433 Enterically coated cysteamine, cystamine and derivatives thereof ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fuji
Johnson and Johnson
Queensland Health
Farmers Insurance
Boehringer Ingelheim
Teva
Daiichi Sankyo
Express Scripts
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.